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The Ci inhibitor of the complement cascade forms stoichiometric complexes with Cir and Cis and controls the activation of first component Cl 
of complement. Literature sedimentation coefficients s‘ 20.w for the complexes formed between Ci inhibitor, Cir and Cis were analysed using 
frictional ratios and the hydrodynamic sphere approach. A head-and-tail two-domain model for Ci inhibitor was combined with cylindrical hydro- 
dynamic models for the six-domain structures of Cir and Cis. The hydrodynamic data show that the heavily glycosylated N-terminal domain 
of Ci inhibitor is positioned close to the two complement ‘short consensus repeat’ domains found in the centre of Cir and Cis. 
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1. INTRODUCTION 
Cl, the first component of the classical pathway of 
the complement cascade, is a complex formed between 
two large distinct multidomain subunits, Clq and 
tetrameric Clr2Clsz. Clq provides the recognition ele- 
ment of Cl for binding to immune complexes, while the 
enzymatic activity of Cl resides in two proteins Clr and 
C~S that bind to Clq. The control of Cl activation to 
C 1 is an essential aspect of the complement cascade [ 11. 
This is achieved by Cl inhibitor, a member of the 
SERine Proteinase INhibitor (SERPIN) superfamily 
PI. 
rnodelling with these data to analyse structures for the 
interaction between Ci inhibitor and each of Cir and 
(37s [lO,ll]. This will identify the arrangement of the 
domains in Cl inhibitor relative to those within Cir 
and Cls in the complexes. 
2. RESULTS AND DISCUSSION 
2.1. Hydrodynamic analyses of CT inhibitor, C?r and 
CI inhibitor is a two-domain protein which binds 
with the six-domain proteins Cir and Cis, the activated 
forms of Clr and Cls, and removes these from CI [2]. 
The serpin domain of Cl inhibitor reacts with the serine 
proteinase domain found in each of Cir and Cls. Little 
is known of the structure of their complexes. The solu- 
tion structures of the domains within CT inhibitor, Clr 
and Cls have been recently studied by neutron scatter- 
ing and hydrodynamic analyses [3,4]. Improved deter- 
minations of their molecular weights from sequence 
data are now available [5-71. Extensive sedimentation 
coefficient s?o,~ data on these proteins and the com- 
plexes formed between them have been published by 
Colomb and coworkers, however, these data have not 
been interpreted by structural analyses [8,9]. It is now 
possible using the method of hydrodynamic sphere 
Neutron scattering analyses show that CT inhibitor is 
18 nm in length, and can be constructed from a serpin 
domain of size 7 x 3 x 3 nm, and an N-terminal do- 
main of length 15 nm [4]. Most reports of the sedimen- 
tation coefficient ~50 ,W of CI inhibitor fall in a range of 
3.67-3.8 S (Table I). A distinct two-domain head-and- 
tail hydrodynamic sphere mode1 of length 1.5 nm to 
18 nm gives a good account of these s%,~ data [4]. Sim- 
ple hydrodynamic rods were shown to lead to 
overestimated lengths for Ci inhibitor [4], and were not 
used further in the modelling of the complexes below. 
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Clr and Cls are each constructed from six domains 
denoted I to VI (Fig. 1) [6,7]. Calculations of their 
overall lengths from neutron scattering and electron 
microscopy suggest values of 25, 16 or 21-26 nm 
[3,12,13]. The use of both the hydrodynamic sphere 
and rod methods to analyse sZO,~ values for C lr and Cl s 
leads to lengths between 17 and 20 nm in satisfactory 
agreement with these other studies [3]. Clr II is a pro- 
teolysed form of Clr that contains only the serine pro- 
teinase domain VI and two complement ‘short 
consensus repeat’ (SCR) domains IV and V. This has a 
hydrodynamic length of 9-l 1 nm [3]. 
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Table I 
Comparisons of experimental and calculated sedimentation coefficients 
Macromolecule M, Hydrated sso.* (S) Frictional [Length 
(x lo-‘) volume ratio, (nm) 
(run”) Experi- Calcu- f/f;1 
mental lated 
Monomers 
Clr 86 143 5.1 5.0 1.27 17 
Clr II 50 84 4.1 3.8 1 .OY Y 
Cl.\ 79 132 4.5 3.5 1.36 19 
Cl inhibitor 71 117 3.67-3.8 3.8, 3.5 1.54 IX, I’ 
Dimers 
Clr’Cl inhibitor 157 260 6.5 6.5, 6.3 1.39 ‘I, 18 
Clr II.Cl inhibitol- 121 201 5.8 5.5, 5.3 I .A0 21, 17 
Cls.Cl inhibitor 150 249 6.1 6.1, 5.9 I.54 21, 20 
Tetramers 
Cls2’CI inhibitorz 300 499 7.7 7.Y, N.C. 1.93 39, 39 
Clr.Cls.Cl inhibitor1 307 509 8.5 8.3, N.C. 1.79 37, 37 
For Cl inhibitor, the sources of &,, data are summarised in [4]; those for Clr. Clr II and Cls 
are summarised in [3]. Those for the Cl inhibitor complexes are given in (8,Y]. The hydrated 
volume corresponds to the sum of the dry glycoprotein volume and the hydration shell ~olurne 
assuming a hydration of 0.3 g HzO/g glycoprotein and an electrortricted water molecule volume 
of 0.0245 nm’, and this leads to partial specific volumes v [16,17], e.g., 0.721 ml ‘g for Cl 
inhibitor. Frictional ratios f/J0 are calculated from _/” = M,(l -- L’Q)/,V.,&, for the 
macromolecule cf, frictional coefficient; Iv,, Avogadro’s contant; M,, molecular weight) and 
from f0 = 6nq, where f0 is the frictional coefficient of the Fphere (radius a) \lith the same 
hydrated volume as the macromolecule (e, buffer density; 7, buffer viscosity). When 
hydrodynamic spheres are used, this hydration is increased to 0.39 g in order to compensate for 
the void spaces between the non-overlapping spheres [l I]. For Cl inhibitor, the protein sphere5 
are 1.69 nm diameter and the carbohydrate spheres are 0.95 nm diameter [4]. The Clr, Clr II 
and Cls models are those of [3], with cpherc diameters of 4,186 nm, 4.417 nm and 3.786 nm in 
that order. Calculations were performed uting the program GENDIA [IX]. The results fol- the 
Cl inhibitor calculations correspond firstly to the compact carbohydrate htructure, then the 
extended one, as presented in [4]. N.C., not computable for reason of computer memor) 
limitations. 
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2.2. Complexes formed between CI inhibitor and Clr 
and Cls 
Literature ss)~,~ data from sucrose density gradient 
ultracentrifugation [14] are summarised in Table I for 
the complexes of CT inhibitor with each of Clr, Clr II 
and Cls [8,9]. The most recent molecular weight deter- 
minations from sequences are given in Table I. Note 
that the revised value for Cl inhibitor is now 71000 as 
a result of DNA and carbohydrate sequencing and 
supersedes previous estimates close to 100000 [2,4]. 
The partial specific volumes of Clr, Cls and Cl in- 
hibitor lie in a restricted range of 0.721-0.725 ml/g 
[3,4] as required [14]. The frictional ratios f/fc) (Table 
I) for Clr, Cls and Cl inhibitor are similar in a range 
of 1.3-1.5, while that for Clr II is less at 1.1, as ex- 
pected from the hydrodynamic lengths summarised 
above (Table I). Calculations of f/f0 for the three 
dimeric complexes in Table I show that these fall in a 
similar range of 1.4- 1.5, and therefore that the dimers 
are as elongated as uncomplexed Cl inhibitor. The f/f0 
values for the tetrameric complexes are larger at 
1.8-1.9, and are more elongated than the monomers 
and dimers. 
Hydrodynamic sphere models were used to account 
90 
for the s%,,,+ data (Table I). It is known that the serine 
proteinase domain VI in Clr, Clr II and Cls is posi- 
tioned at one end of the six-domain structure of 
hydrodynamic length 17-20 nm [ 13,151. The modelling 
of the complexes is accordingly constrained so that do- 
main VI is close to the serpin domain of Cl inhibitor. 
Two calculations of the s~o,~ and length are reported 
for Cl inhibitor and its complexes in Table I. These 
correspond to controls in which the 26% carbohydrate 
content of Cl inhibitor is either indistinguishable from 
the protein surface or positioned in an extended con- 
figuration as in Fig. l(a) [4]. 
Good agreement with the experimental .s$),~ data for 
the five complexes was obtained only for the most com- 
pact models that were tested, e.g., that for Cls when 
aligned in the +x direction from the contact with the 
serpin domain in Fig. 1. These models position the N- 
terminal domain of Cl inhibitor close to the two SCR 
domains IV and V at the centre of Clr and Cls [3]. 
Table I shows that the Cl inhibitor complexes with 
Cl r, Cir II and Cls have hydrodynamic lengths bet- 
ween 18 and 21 nm, which are similar to those of 
15-19 nm for free Cl inhibitor, Clr and Cls. The 
calculated and experimental .Y$~,~ values for the dimers 
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Fig. 1. Schematic model for the interaction of Cl inhibitor with Cls in a dimeric complex. (a) Perspective view of the hydrodynamic sphere model 
successfully used to account for the experimental &., of Cl inhiibtor [4]. The serpin domain is at the rear; the N-terminal domain (5 spheres 
as stippled) with extended oligosaccharide chains is in the foreground. (b) A side-view of the Cl inhibitor complex with Cls indicates the family 
of models successfully used for the dimer in Table 1. In Cls, I, II and 111 correspond to the ‘interaction’ domains, IV and V to the two complement 
‘short consensus repeat’ domains, and VI to the serine proteinase domain. The 5 spheres used to represent Cls result from the modelling and 
do not relate to the domain structure of Clr or Cls. The hydrodynamic data report on the overall length of the macromolecule, so the contact 
shown between the two components of the complex can only be schematic. 
agree to within 0.0-0.3 S, which is acceptable given 
that the accuracy of each of the calculations and the ex- 
periments is generally within ? 0.2 S [l 11. 
In contrast, tests of more extended dimer models 
lead to large differences with the experimental data. 
Models in which Cir and Cls extend along the other 
possible (-x, +y, +z and -z) directions from the con- 
tact site (Fig. 1) give rise to calculated .s~o,~ values that 
are 0.4 S to 0.7 S less than the experimental values for 
the compact carbohydrate Cl inhibitor model and bet- 
ween 0.6 S to 0.9 S for the extended carbohydrate Cl 
inhibitor model. The magnitude of these differences 
argues against the existence of these structures for the 
dimeric complexes. 
In the two tetrameric complexes of Cl inhibitor with 
Cir and Cls, the +x dimers were positioned in an end- 
to-end linear arrangement. The sphere(s) correspon- 
ding to domains I, II and III in each of Cir and CIs are 
in tangential contact with each other. Biochemically, 
these contacts correspond to those found in the Clsz 
dimer and Clr2Clsz tetramer. This doubled the length 
of the tetramer relative to that of the monomer (Table 
I). Good agreements between the calculated and ex- 
perimental sTO,W data were obtained with these models 
(Table I). This is further support for the compact 
nature of the interaction between Cl inhibitor and each 
of Clr and Cls. 
3. CONCLUSIONS 
Hydrodynamic analyses of literature s%,,, data on Cl 
inhibitor and its complexes can now be interpreted us- 
ing recent sequence and structural data. The f/f0 ratios 
and the sphere modelling both support the result that 
the complexes contain compact arrangements of Cir, 
Cls and CI inhibitor, and this result can be refined us- 
ing other techniques. 
A hypothesis can be proposed for the role of the N- 
terminal domain of Cl inhibitor. Models such as those 
of Fig. l(b) show that the steric accessibility of the two 
SCR domains VI and V at the centre of Clr and Cis 
will be reduced by the N-terminal domain of CT in- 
hibitor after the serpin domain of Cl inhibitor has in- 
teracted with the serine proteinase domain VI of Clr 
and Cls. It can be postulated that this reduced ac- 
cessibility will influence the binding affinity of C lr and 
Cls to Clq and likewise for that of Cls with C4 of 
complement. In other words, the inhibitors of multi- 
domain serine proteinases may themselves require a 
multi-domain structure in order to perform their 
physiological role. 
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